Page Image

HER2 Breast Cancer

Back to Homepage
Zanidatamab Plus Chemo Shows Response in HER2+ and HER2-Low mBC
Zanidatamab plus chemo showed promising responses in HER2+ and HER2-low mBC, with durable activity in a phase I trial.
Advertisement

Expert Interviews

Advertisement
Advertisement
Latest Breast Cancer News

May 22, 2025